Mini Review

Pharmacognosy of marine natural products: Potential for drug discovery

Harish Kumar Mishra

Department of Pharmacology, KITS University, Uttar Pradesh, India

Correspondence:
Dr. Harish Kumar Mishra, Department of Pharmacology, KITS University, Uttar Pradesh, India.
E-mail id: harish.mishra76@gmail.com

How to cite this article:
Mishra HK. Pharmacognosy of marine natural products: Potential for drug discovery. Innov Pharm Pharmacother 2023;11(3):48-52.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 10-07-2023
Date of Revision: 28-07-2023
Date of Acceptance: 05-08-2023

ABSTRACT

Marine natural products (MNPs) are gaining significant attention in drug discovery due to their unparalleled chemical diversity and potent bioactivity. Derived from the vast biodiversity of marine ecosystems, including bacteria, fungi, algae, and invertebrates, MNPs offer novel molecular scaffolds and mechanisms of action, making them promising candidates for therapeutic development. Clinically successful drugs such as ziconotide, trabectedin, and cytarabine exemplify the therapeutic potential of marine-derived compounds, particularly in anticancer, antimicrobial, and neuroprotective applications.Despite their immense promise, challenges persist in the exploration and utilization of MNPs.These include limited accessibility to underexplored habitats like deep-sea ecosystems, sustainability concerns regarding resource extraction, and technical hurdles in isolating and synthesizing complex bioactive compounds. Legal and ethical complexities surrounding biodiversity laws and intellectual property rights further complicate marine pharmacognosy. Advancements in synthetic biology, genomic sequencing, and bioinformatics are enabling innovative solutions to these challenges, facilitating the identification, characterization, and sustainable production of marine bioactive compounds. Interdisciplinary collaborations and public-private partnerships are essential for translating MNP discoveries into viable clinical applications. The field of marine pharmacognosy represents an underutilized yet transformative avenue for addressing unmet medical needs. By leveraging emerging technologies and sustainable practices, researchers can unlock the vast potential of MNPs, paving the way for novel therapeutics that address global health challenges.

Keywords: Anticancer, antimicrobial, bioactive compounds, biodiversity, drug discovery, Marine natural products, neuroprotective, pharmacognosy, sustainability, synthetic biology

Introduction

Marine natural products (MNPs) have emerged as a significant area of interest in drug discovery due to their unique chemical structures and biological activities. The oceans, covering nearly 70% of the Earth's surface, host an immense biodiversity that includes a vast array of organisms such as bacteria, fungi, algae, and invertebrates. This biodiversity is a treasure trove for discovering novel compounds that may lead to new therapeutic agents.

Access this article online

Website: https://innovationaljournals.com/index.php/ip | e-ISSN: 2348-7275

DOI: 10.31690/ipplanet.2023.v011i03.013

Importance of MNPs in Drug Discovery

The exploration of MNPs is crucial for several reasons

Chemical diversity

Marine organisms produce a wide range of bioactive compounds that are often structurally distinct from terrestrial natural products. This chemical novelty is essential for discovering new drugs with unique mechanisms of action.[1]

Therapeutic potential

Many MNPs exhibit significant pharmacological properties, including anticancer, antimicrobial, and anti-inflammatory activities. For instance, ziconotide, derived from the venom of the cone snail, was the first marine-derived drug approved by the FDA in 2004.[2,3]

Unmet medical needs

MNPs offer potential solutions for diseases that currently lack effective treatments. The increasing interest in marine pharmacognosy is driven by the need for new therapeutic agents to combat various health challenges.[4]

Overview of marine biodiversity

Marine biodiversity is unparalleled compared to terrestrial ecosystems. The ocean hosts approximately 34-36 phyla, many of which have no terrestrial counterparts. This diversity is not only important for ecological balance but also represents a vast reservoir of potential pharmaceutical compounds. Key points include:

Unique organisms

Many marine species possess unique adaptations that result in the production of novel metabolites. For example, sponges and soft corals have been identified as rich sources of bioactive compounds.[5]

Microbial symbionts

A significant number of bioactive compounds are produced by microbial symbionts associated with marine organisms. These microbes often engage in chemical warfare against competitors, leading to the production of potent antibiotics and other pharmaceuticals.[6]

Underexplored habitats

Despite the vastness of marine environments, many areas remain underexplored, particularly deep-sea ecosystems. Advances in technology are facilitating access to these habitats and uncovering new classes of natural products.[5]

MNPs as Drug Sources

Unique features of marine-derived compounds

MNPs are distinguished by their chemical diversity and unique structural features that often differ significantly from terrestrial compounds. Key characteristics include:

Chemical novelty

Approximately 71% of the molecular scaffolds found in MNPs are exclusive to marine organisms, highlighting their potential for novel drug discovery.[7]

Bioactivity

MNPs demonstrate a higher incidence of significant bioactivity compared to terrestrial natural products. For example, preclinical screens show that about 1% of marine samples exhibit anti-tumor activity, compared to 0.1% from terrestrial sources.

Ecological roles

Many MNPs serve as chemical defenses for marine organisms against predators and pathogens, which contributes to their bioactive properties.[8]

Examples of successful drugs from marine sources

Several marine-derived compounds have successfully transitioned into clinical use, showcasing the potential of MNPs in pharmacotherapy:

Cytarabine (Ara-C)

The first FDA-approved marine-derived drug, approved in 1969 for cancer treatment, is derived from nucleosides isolated from the Caribbean sponge Tethya crypta.

Ziconotide (Prialt®)

Approved in 2004 for severe chronic pain management, this drug is a synthetic equivalent of a peptide from the venom of the cone snail Conus magus.

Trabectedin (Yondelis®)

This marine alkaloid, isolated from the tunicate Ecteinascidia turbinata, received EU approval in 2007 for treating soft-tissue sarcoma and relapsed ovarian cancer.

Eribulin mesylate (Halaven™)

Gaining FDA approval in 2010 for metastatic breast cancer, this drug is a simplified analog of Halichondrin B, initially derived from the sponge Halichondria okadai.[7]

Pharmacognosy of MNPs

Key bioactive compounds

MNPs encompass various classes of bioactive compounds with significant therapeutic potential:

Alkaloids

These nitrogen-containing compounds often exhibit potent biological activities. Trabectedin is an example of a marine alkaloid with anticancer properties.

Polyketides

Known for their structural complexity and diverse biological activities, polyketides are produced by various marine organisms and have applications in antibiotic and anticancer therapies.

Peptides

Marine peptides, such as ziconotide, are notable for their analgesic properties. However, their peptidic nature presents challenges in terms of stability and bioavailability.

Terpenes

This class includes a variety of compounds with anti-inflammatory and anticancer activities. Their structural diversity contributes to their wide range of biological effects.[5]

Structural Diversity and Challenges in Characterization

The structural diversity of MNPs poses both opportunities and challenges

Complex structures

The intricate structures of many MNPs complicate their characterization and synthesis. Advanced techniques such as NMR spectroscopy and mass spectrometry (MS) are essential for elucidating these structures.[9]

Supply issues

Many bioactive compounds are produced in low yields by their natural sources, necessitating innovative approaches such as synthetic biology or semi-synthesis to enhance availability.

Metabolic stability

Peptide-based drugs often face metabolic degradation challenges. Medicinal chemistry strategies are being employed to modify these compounds to improve their pharmacokinetic properties.[3]

Potential Applications in Drug Discovery

Anticancer agents

MNPs have shown significant promise as anticancer agents due to their unique bioactive compounds. The ecological role of these compounds often involves chemical defense mechanisms, which can be harnessed for therapeutic purposes. Notable examples include:

Trabectedin (Yondelis®)

Derived from the tunicate Ecteinascidia turbinata, this drug is used for soft-tissue sarcoma and ovarian cancer.

Dolastatin 10

Isolated from the sea hare Dolabella auricularia, it has been developed into antibody-drug conjugates for targeted cancer therapy, demonstrating the potential for MNPs to enhance treatment efficacy while minimizing side effects.[10]

Antimicrobial and antiviral compounds

The marine environment is a rich source of antimicrobial and antiviral agents, with many compounds exhibiting potent activity against a variety of pathogens:

Marine bacteria

Certain marine-derived bacteria produce antibiotics that are effective against resistant strains of bacteria. For instance, Salinispora tropica has yielded compounds with significant antibacterial properties.

Antiviral activities

MNPs have also shown promise against viruses, including those responsible for influenza and HIV. Research continues to explore the mechanisms by which these compounds exert their antiviral effects.[11]

Neuroprotective agents

MNPs are being investigated for their neuroprotective properties, which could lead to new treatments for neurodegenerative diseases:

Peptides from marine sources

Compounds such as conotoxins from cone snails have demonstrated potential in modulating neurotransmitter systems and protecting neuronal cells from degeneration.

Bioactive lipids

Certain lipids derived from marine organisms exhibit anti-inflammatory and neuroprotective effects, suggesting their utility in treating conditions like Alzheimer's disease.[12]

Anti-inflammatory and immunomodulatory drugs

The anti-inflammatory properties of MNPs make them attractive candidates for developing drugs targeting inflammatory diseases:

Sulfated polysaccharides

Extracted from marine algae, these compounds have shown immunomodulatory effects and are being researched for their potential in treating autoimmune diseases.

Terpenes

Marine-derived terpenes possess anti-inflammatory properties that may be beneficial in managing conditions such as arthritis and other inflammatory disorders.[13]

Techniques in Exploring MNPs

Collection and identification of marine organisms

Advancements in sampling techniques have significantly improved the collection of marine organisms. Methods now include:

Metagenomics

This approach allows researchers to analyze genetic material directly from environmental samples, facilitating the discovery of novel marine species and their associated bioactive compounds.

Remote sensing technologies

These technologies aid in locating unexplored marine habitats, such as deep-sea environments, where unique organisms may reside.[14]

Extraction and Isolation of Bioactive Compounds

The extraction and isolation processes are critical steps in drug discovery

Solvent extraction

Traditional methods using organic solvents are commonly employed to extract bioactive compounds from marine organisms. However, new methods such as microwave-assisted extraction are gaining traction due to their efficiency.

Chromatography techniques

High-performance liquid chromatography and other chromatographic methods are essential for isolating pure compounds from complex mixtures.[15]

Advances in Analytical Techniques

Recent advancements in analytical techniques enhance the characterization of MNPs

Nuclear magnetic resonance (NMR) spectroscopy

NMR is pivotal for elucidating the structures of complex marine compounds, providing insights into their chemical properties.

MS

Coupled with chromatographic techniques, MS allows for rapid identification and characterization of bioactive compounds at low concentrations.

Computational methods

Advances in bioinformatics and computational chemistry facilitate the prediction of biological activities based on molecular structures, streamlining the drug discovery process.[16]

Challenges and Limitations

Accessibility and sustainability of marine resources

The exploration and utilization of MNPs face significant challenges related to accessibility and sustainability:

Geographic accessibility

Many marine environments, particularly deep-sea habitats, remain largely unexplored due to their inaccessibility. This limits the collection of diverse marine organisms that could yield novel bioactive compounds.[17]

Sustainability concerns

The collection of marine organisms must be conducted sustainably to prevent overharvesting and ecological damage. Sustainable practices, such as aquaculture and mariculture, are essential to ensure a continuous supply of marine resources without harming the ecosystem.[18]

Legal and Ethical Considerations

Legal and ethical issues also pose challenges in the field of marine pharmacognosy

Biodiversity laws

International agreements, such as the Convention on Biological Diversity, regulate access to genetic resources and benefit-sharing. Compliance with these regulations is crucial for ethical research practices.[19]

Intellectual property rights

The patenting of natural products derived from marine organisms raises ethical questions regarding the ownership of biological resources and the fair distribution of benefits derived from their commercialization.

Technical and Financial Constraints

Technical and financial limitations hinder the advancement of MNPs in drug discovery

High costs

The costs associated with marine drug development, including extensive clinical trials, can be prohibitively high. Pharmaceutical companies may hesitate to invest in MNPs due to uncertain return on investment.[20]

Technical expertise

The complexity of isolating and characterizing bioactive compounds requires specialized knowledge and advanced technologies, which may not be readily available in all research settings.

Future Directions

Emerging technologies in marine pharmacognosy

The future of marine pharmacognosy is promising, driven by emerging technologies that enhance drug discovery:

Synthetic biology

Advances in synthetic biology allow for the engineering of microbial systems to produce marine-derived compounds at scale. This could alleviate supply issues associated with low-yield natural sources.

Genomic approaches

The use of genomic sequencing techniques helps identify biosynthetic gene clusters responsible for producing bioactive compounds, facilitating the discovery of new MNPs.[21]

Collaborative efforts for sustainable utilization

Collaboration among various stakeholders is essential for the sustainable utilization of marine resources:

Interdisciplinary research

Collaborative efforts between biologists, chemists, oceanographers, and policymakers can lead to innovative approaches in exploring and conserving marine biodiversity while promoting drug discovery.[22]

Public-private partnerships

Engaging with industry partners can help bridge the gap between research and commercialization, ensuring that promising MNPs are developed into marketable drugs.

Promising areas for further research

Several areas present exciting opportunities for further research in marine pharmacology:

Underexplored habitats

Continued exploration of less-studied marine environments, such as deep-sea ecosystems, could yield novel compounds with unique therapeutic properties.

Microbial symbionts

Investigating the role of microbial symbionts associated with marine organisms may uncover new classes of bioactive compounds that have yet to be studied extensively.

Drug delivery systems

Developing innovative drug delivery systems utilizing MNPs could enhance the efficacy of existing therapies while minimizing side effects.

Conclusion

MNPs are a promising yet underutilized resource for drug discovery, offering unique chemical diversity and potent therapeutic potential. Their success in yielding clinically useful drugs highlights their value, especially in treating cancers, chronic pain, and infectious diseases.

However, challenges such as limited access to marine resources, sustainability concerns, legal complexities, and technical hurdles in isolating and characterizing MNPs hinder their broader application.

To overcome these barriers, there is a need for increased research funding, interdisciplinary collaboration, and sustainable harvesting methods. Emerging technologies like synthetic biology and artificial intelligence hold significant promise for accelerating discovery and development.

With concerted efforts to address these challenges, the pharmacognosy of MNPs can unlock groundbreaking therapeutic solutions, paving the way for innovative treatments and advancing global healthcare.

References

1. Ojemaye CY, Petrik L. Pharmaceuticals in the marine environment: A review. Environ Rev 2019;27:151-65.
2. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009;8:69-85.
3. Bisaria K, Sinha S, Srivastava A, Singh R. Marine pharmacognosy: An overview of marine-derived pharmaceuticals. In: Marine Niche: Applications in Pharmaceutical Sciences: Translational Research. Germany: Springer Nature; 2020. p. 361-381.
4. Mezzelani M, Gorbi S, Regoli F. Pharmaceuticals in the aquatic environments: Evidence of emerged threat and future challenges for marine organisms. Mar Environ Res 2018;140:41-60.
5. Almaliti J, Gerwick WH. Methods in marine natural product drug discovery: What's new? Expert Opin Drug Discov 2023;18:687-91.
6. Oliver JM, Ross EL, Frank EK. The discovery of marine natural products with therapeutic potential. Biotechnology 1994;26:109-74.
7. Montaser R, Luesch H. Marine natural products: A new wave of drugs? Future Med Chem 2011;3:1475-89.
8. Jiménez C. Marine natural products in medicinal chemistry. ACS Med Chem Lett 2018;9:959-61.
9. Lu WY, Li HJ, Li QY, Wu YC. Application of marine natural products in drug research. Bioorg Med Chem 2021;35:116058.
10. Faulkner DJ. Marine natural products. Nat Prod Rep 2001;18:1-49.
11. Blunt JW, Copp BR, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep 2006;23:26-78.
12. Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep 2022;39:1122-71.
13. Hu GP, Yuan J, Sun L, She ZG, Wu JH, Lan XJ, *et al*. Statistical research on marine natural products based on data obtained between 1985 and 2008. Mar Drugs 2011;9:514-25.
14. Bhakuni DS, Rawat DS. Bioactive Marine Natural Products. Germany: Springer Science and Business Media; 2006.
15. Gerwick WH, Moore BS. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem Biol 2012;19:85-98.
16. Pereira F. Have marine natural product drug discovery efforts been productive and how can we improve their efficiency? Expert Opin Drug Discov 2019;14:717-22.
17. Lindequist U. Marine-derived pharmaceuticals-challenges and opportunities. Biomol Ther (Seoul) 2016;24:561-71.
18. Ahmed I, Asgher M, Sher F, Hussain SM, Nazish N, Joshi N, *et al*. Exploring marine as a rich source of bioactive peptides: Challenges and opportunities from marine pharmacology. Mar Drugs 2022;20:208.
19. Papon N, Copp BR, Courdavault V. Marine drugs: Biology, pipelines, current and future prospects for production. Biotechnol Adv 2022;54:107871.
20. Saeed AF, Su J, Ouyang S. Marine-derived drugs: Recent advances in cancer therapy and immune signaling. Biomed Pharmacother 2021;134:111091.
21. Allen MJ, Jaspars M. Realizing the potential of marine biotechnology: Challenges and opportunities. Ind Biotechnol 2009;5:77-83.
22. Jeon YJ, Samarakoon KW, Elvitigala DA. Marine-derived pharmaceuticals and future prospects. In: Springer Handbook of Marine Biotechnology. Germany: Springer; 2015. p. 957-68.